2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-171295
    p38 Kinase inhibitor 7 815595-14-3 98%
    p38 Kinase inhibitor 7 (Comp:XXXIX) is the inhibitor for p38α with an IC50 of 5.25 nM. p38 Kinase inhibitor 7 inhibits TNFα production in cell THP-1 with an IC50 of 5.88 nM.
    p38 Kinase inhibitor 7
  • HY-171296
    p38 Kinase inhibitor 8 815595-25-6 98%
    p38 Kinase inhibitor 8 (Compound CCLXXVIII) is the orally active inhibitor for p38β and JNK2α2 with IC50s of 6.3 nM and 53.6 nM. p38 Kinase inhibitor 8 exhibits anti-inflammatory effect in rats collagen-induced arthritis models.
    p38 Kinase inhibitor 8
  • HY-171448
    SU-740 134336-72-4 98%
    SU-740 is a chalcone derivative with anti-ulcer activity.
    SU-740
  • HY-171460
    Win 45164 83880-39-1 98%
    Win 45164 is an orally active glucocorticoid receptor (Glucocorticoid Receptor) ligand with the activity of inhibiting the pituitary - adrenal axis. It can promote liver glycogen deposition and thymus involution in adrenalectomized male rats. Meanwhile, Win 45164 has anti - inflammatory effects. It can be used in the research of inflammatory and neurological diseases.
    Win 45164
  • HY-171462
    SMW139 2133010-38-3 98%
    SMW139 is a selective allosteric antagonist of P2X7 receptor, with a Ki value of 32 nM for human P2X7R. The half-life of SMW139 in rat liver microsomes is 47 minutes. SMW139 can be used for inflammation, Alzheimer’s disease, multiple sclerosis study.
    SMW139
  • HY-171470
    RS-57067 179382-91-3 98%
    RS-57067 is a COX-2 inhibitor with a Ki of 16.9 μM. RS-57067 reduces the production of prostaglandins (such as PGE2) by inhibiting COX-2, thereby alleviating the inflammatory response. RS-57067 can be used in the research of inflammatory and immune diseases.
    RS-57067
  • HY-171476
    CP-865569 478833-25-9 98%
    CP-865569 is a CCR1 antagonist. CP-865569 can be used in the research of inflammatory diseases and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.
    CP-865569
  • HY-171831
    Leukotriene E3 79494-05-6
    Leukotriene E3 is a cysteinyl leukotriene metabolite derived from 5,8,11-eicosatrienoic acid (HY-108398A). Leukotriene E3 acts as a smooth-muscle-contracting mediator. Leukotriene E3 can be used for the research of allergic reactions and asthma.
    Leukotriene E3
  • HY-171906
    1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA 65446-08-4 98%
    1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA is a phospholipid containing arachidonic acid at the sn-1 position. It is a precursor to 1-arachidonoyl glycerol (1-Monoarachidin; HY-130567). 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA binds to the LPA2/EDG4 receptor with an EC50 value of approximately 10 nM. It prevents TNF-α and IL-6 secretion in wild-type but not Lpa2-/- dendritic cells stimulated by LPS. It also decreases differentiation of HT-29 human colon carcinoma cells to goblet cells in the presence of sodium butyrate.
    1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA
  • HY-172167
    PD-L1/HDAC-IN-1 2923313-69-1 98%
    PD-L1/HDAC-IN-1 (Compound 14) is the inhibitor for PD-L1 and HDAC that inhibits PD-1/PD-L1 interaction, HDAC2 and HDAC3 with IC50 of 88.10, 27.98 and 14.47 nM, respectively. PD-L1/HDAC-IN-1 exhibits slight cytotoxicity in MCF-7 (IC50=19.34 μM). PD-L1/HDAC-IN-1 upregulates the expression of PD-L1 and CXCL10, promoting anti-tumour immune response by recruiting T-cell infiltration into TME.
    PD-L1/HDAC-IN-1
  • HY-172195
    FS-694 1417404-27-3 98%
    FS-694, a chemical probe, is the inhibitor for p38α with an IC50 of 0.2 nM. FS-694 inhibits the TNFα release in human whole blood with an IC50 of 35.0 nM.
    FS-694
  • HY-172750
    17(R,S)-Benzo-resolvin D1
    17(R,S)-Benzo-resolvin D1 (17(R,S)-Benzo-RvD1) is a Resolvin D1 (HY-125527) analogue with pro-resolving and anti-migratory activity. 17(R,S)-Benzo-resolvin D1 attenuates neointimal hyperplasia in a rat model of acute vascular injury.
    17(R,S)-Benzo-resolvin D1
  • HY-173077
    PD-L1/LpxC-IN-1 98%
    PD-L1/LpxC-IN-1 (Conpound 12b) is the inhibitor for PD-L1 and LpxC with IC50 of 5.2 μM and 0.081 μM. PD-L1/LpxC-IN-1 inhibits the biosynthesis of bacterial lipopolysaccharide, causes the lysis and death of bacterial cells. PD-L1/LpxC-IN-1 inhibits Gram-negative bacteria, MIC for K. pneumoniae ATCC 13883, E. coli ATCC 8739, S. typhimurium ATCC 14028 and P. aeruginosa ATCC 9027 is 0.25-0.5 μg/mL. PD-L1/LpxC-IN-1 downregulates the expression of inflammatory factors IL-2 and IFN-γ, upregulates the expression of CD4+ and CD8+ cells, thereby activating the immune system and inhibiting excessive inflammatory responses. PD-L1/LpxC-IN-1 exhibits antibacterial activity in K. pneumoniae ATCC 13883 infected mouse models.
    PD-L1/LpxC-IN-1
  • HY-173204
    Influenza virus-IN-9 98%
    Influenza virus-IN-9 (12) is an influenza endonuclease inhibitor, with an IC50 of 0.03 μM.
    Influenza virus-IN-9
  • HY-173213
    Antileishmanial agent-33 98%
    Antileishmanial agent-33 (4e), a hybrid compound of grandisin and machilin G, shows moderate activity on promastigotes (IC50 of 38.1 μM). Antileishmanial agent-33 (4e) shows potential as an antileishmanial agent for the research of cutaneous leishmaniasis (CL).
    Antileishmanial agent-33
  • HY-173215
    3-Dimethylaminopropyl deacetylforskolin 98%
    3-Dimethylaminopropyl deacetylforskolin is a dehydro derivative of adenylate cyclase activator Forskolin (HY-15371) and may cause cross-immunoreactivity with anti-Forskolin antibodies.
    3-Dimethylaminopropyl deacetylforskolin
  • HY-173285
    SARS-CoV-2 Mpro-IN-38 98%
    SARS-CoV-2 Mpro-IN-38 (2-5a) is a SARS-CoV‑2 Mpro inhibitor, with an IC50 of 0.0435 μM.
    SARS-CoV-2 Mpro-IN-38
  • HY-173298
    PDHK1-IN-2 2870691-38-4 98%
    PDHK1-IN-2 (Compound 24) is an ATP-competitive dual inhibitor of pyruvate dehydrogenase kinases 1/2 (PDHK1/2), with an IC50 of 0.007 μM for PDHK1 and an IC50 of 0.015 μM for PDHK2. PDHK1-IN-2 can regulate immune cell metabolism and correct mitochondrial dysfunction, and is expected to be used in the research of autoimmune diseases, inflammatory diseases, cancers, and other conditions.
    PDHK1-IN-2
  • HY-173301
    PDHK1-IN-3 98%
    PDHK1-IN-3 (Compound 29) is a selective PDHK1 inhibitor with an IC50 of 0.028 μM against PDHK1 and an IC50 of 0.120 μM against PDHK2. PDHK1-IN-3 inhibits the activity of PDHK1 by forming a covalent bond with Lys299 in PDHK1. PDHK1-IN-3 can be used in the research of autoimmune diseases, inflammatory diseases, and cancer.
    PDHK1-IN-3
  • HY-173356
    Antiparasitic agent-26 98%
    Antiparasitic agent-26 (Compound 8) is an antiparasitic compound that potently inhibits the growth of Naegleria fowleri, with IC50 values of 22.87 μM (trophozoite stage) and 25.16 μM (cyst stage). Antiparasitic agent-26 exerts its antiparasitic activity by inducing programmed cell death, including cytoplasmic calcium accumulation, mitochondrial membrane potential collapse, ATP synthesis inhibition, ROS accumulation, and chromatin condensation. Antiparasitic agent-26 can be used in the research of primary amoebic meningoencephalitis (PAM).
    Antiparasitic agent-26
Cat. No. Product Name / Synonyms Application Reactivity